Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS trial of ziltivekimab after acute myocardial infarction
MOH_2024-04-17_013314Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in myocardial infarction (MI) comparing ziltivekimab with placebo (2 arms). Started Apr 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2024-04-17_013314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-17_013314.